177 related articles for article (PubMed ID: 16763897)
1. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?
Djouadi F; Aubey F; Schlemmer D; Gobin S; Laforet P; Wanders RJ; Strauss AW; Bonnefont JP; Bastin J
J Inherit Metab Dis; 2006; 29(2-3):341-2. PubMed ID: 16763897
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
3. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
Djouadi F; Bastin J
J Inherit Metab Dis; 2008 Apr; 31(2):217-25. PubMed ID: 18392740
[TBL] [Abstract][Full Text] [Related]
4. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
Ørngreen MC; Madsen KL; Preisler N; Andersen G; Vissing J; Laforêt P
Neurology; 2014 Feb; 82(7):607-13. PubMed ID: 24453079
[TBL] [Abstract][Full Text] [Related]
5. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy.
Gobin-Limballe S; Djouadi F; Aubey F; Olpin S; Andresen BS; Yamaguchi S; Mandel H; Fukao T; Ruiter JP; Wanders RJ; McAndrew R; Kim JJ; Bastin J
Am J Hum Genet; 2007 Dec; 81(6):1133-43. PubMed ID: 17999356
[TBL] [Abstract][Full Text] [Related]
6. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
[TBL] [Abstract][Full Text] [Related]
7. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
Lund M; Andersen KG; Heaton R; Hargreaves IP; Gregersen N; Olsen RKJ
Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166100. PubMed ID: 33549744
[TBL] [Abstract][Full Text] [Related]
8. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts.
Bastin J; Lopes-Costa A; Djouadi F
Hum Mol Genet; 2011 May; 20(10):2048-57. PubMed ID: 21378393
[TBL] [Abstract][Full Text] [Related]
9. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.
Djouadi F; Bonnefont JP; Thuillier L; Droin V; Khadom N; Munnich A; Bastin J
Pediatr Res; 2003 Oct; 54(4):446-51. PubMed ID: 12840153
[TBL] [Abstract][Full Text] [Related]
10. Long-chain fatty acid oxidation during early human development.
Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
[TBL] [Abstract][Full Text] [Related]
11. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
Bastin J; Bonnefont JP; Djouadi F; Bresson JL
J Inherit Metab Dis; 2015 Mar; 38(2):371-2. PubMed ID: 25310995
[No Abstract] [Full Text] [Related]
12. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.
Djouadi F; Aubey F; Schlemmer D; Bastin J
J Clin Endocrinol Metab; 2005 Mar; 90(3):1791-7. PubMed ID: 15613406
[TBL] [Abstract][Full Text] [Related]
13. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
Yamada K; Taketani T
J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
[TBL] [Abstract][Full Text] [Related]
14. Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches.
Gobin-Limballe S; McAndrew RP; Djouadi F; Kim JJ; Bastin J
Biochim Biophys Acta; 2010 May; 1802(5):478-84. PubMed ID: 20060901
[TBL] [Abstract][Full Text] [Related]
15. Strategies for correcting very long chain acyl-CoA dehydrogenase deficiency.
Tenopoulou M; Chen J; Bastin J; Bennett MJ; Ischiropoulos H; Doulias PT
J Biol Chem; 2015 Apr; 290(16):10486-94. PubMed ID: 25737446
[TBL] [Abstract][Full Text] [Related]
16. No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.
Ørngreen MC; Vissing J; Laforét P
J Inherit Metab Dis; 2015 Mar; 38(2):373-4. PubMed ID: 25331908
[No Abstract] [Full Text] [Related]
17. Carnitine-acylcarnitine translocase deficiency: Two neonatal cases with common splicing mutation and in vitro bezafibrate response.
Vatanavicharn N; Yamada K; Aoyama Y; Fukao T; Densupsoontorn N; Jirapinyo P; Sathienkijkanchai A; Yamaguchi S; Wasant P
Brain Dev; 2015 Aug; 37(7):698-703. PubMed ID: 25459972
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.
Bonnefont JP; Bastin J; Laforêt P; Aubey F; Mogenet A; Romano S; Ricquier D; Gobin-Limballe S; Vassault A; Behin A; Eymard B; Bresson JL; Djouadi F
Clin Pharmacol Ther; 2010 Jul; 88(1):101-8. PubMed ID: 20505667
[TBL] [Abstract][Full Text] [Related]
19. Different Lipid Signature in Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders.
Alatibi KI; Hagenbuchner J; Wehbe Z; Karall D; Ausserlechner MJ; Vockley J; Spiekerkoetter U; Grünert SC; Tucci S
Cells; 2021 May; 10(5):. PubMed ID: 34069977
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid metabolism in hepatocytes cultured with hypolipidaemic drugs. Role of carnitine.
Gerondaes P; Alberti KG; Agius L
Biochem J; 1988 Jul; 253(1):161-7. PubMed ID: 3048253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]